Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)
Data Collection
Eye Diseases+1
+ Macular Degeneration
+ Retinal Degeneration
Treatment Study
Summary
Study start date: August 1, 1999
Actual date on which the first participant was enrolled.AMD is a progressive disease of the retina which is nourished by a network of tiny blood vessels. There is evidence to suggest that the flow of nutrients to the retina is impaired in patients with AMD. Rheopheresis blood filtration uses blood filters that deplete excesses of large proteins, fats and other substances from the blood, improving blood flow to the macula, potentially improving vision.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.180 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 50 to 85 Years
Range of ages for which participants are eligible to join.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
* Age 50-85 * Diagnosis of Dry AMD * BCVA between 20/32 and 20/125 in at least one eye * Numerous large plaques (soft drusen) * No history of HIV, Hepatitis B or C * Elevation of certain blood factors, such as total cholesterol, fibrinogen, and IgA
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 8 locations
Aran Eye Associates
Coral Gables, United StatesRetina Health Care
Ft. Myers, United StatesUIC Eye Center
Chicago, United States